Loading cancer entity…
Loading cancer entity…
Clinical trials
359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (52)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05445167 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain | completed | Phase 3 | 89 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03271489 | Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women | completed | Phase 3 | 478 | AbbVieINDUSTRY | 2 | Jul 22, 2025 | clinicaltrials |
| NCT05440383 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia | completed | Phase 3 | 287 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06115408 | Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma | completed | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03751124 | Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 229 | Myovant Sciences GmbHINDUSTRY | 8 | Jun 25, 2024 | clinicaltrials |
| NCT03412890 | LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 477 | Myovant Sciences GmbHINDUSTRY | 9 | May 9, 2024 | clinicaltrials |
| NCT03103087 | LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 382 | Myovant Sciences GmbHINDUSTRY | 8 | Apr 20, 2022 | clinicaltrials |
| NCT03049735 | LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 388 | Myovant Sciences GmbHINDUSTRY | 6 | Apr 19, 2022 | clinicaltrials |
| NCT02925494 | An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 433 | AbbVieINDUSTRY | 3 | Jul 13, 2021 | clinicaltrials |
| NCT03070899 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids(PRIMROSE 1) | completed | Phase 3 | 526 | ObsEva SAINDUSTRY | 1 | Jun 9, 2021 | clinicaltrials |
| NCT03070951 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids(PRIMROSE 2) | completed | Phase 3 | 511 | ObsEva SAINDUSTRY | 9 | Mar 5, 2021 | clinicaltrials |
| NCT01629563 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIV) | completed | Phase 3 | 451 | PregLem SAINDUSTRY | 11 | Sep 4, 2019 | clinicaltrials |
| NCT02655224 | A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids | completed | Phase 3 | 65 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT02655237 | A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids | completed | Phase 3 | 281 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT00365989 | MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication | completed | Phase 3 | 50 | InSightecINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT00295217 | MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation | completed | Phase 3 | 15 | InSightecINDUSTRY | 1 | Dec 20, 2018 | clinicaltrials |
| NCT01715597 | Study on the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women With Uterine Myoma | completed | Phase 3 | 50 | Seoul National University HospitalOTHER | 1 | Oct 31, 2017 | clinicaltrials |
| NCT01156857 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIII) | completed | Phase 3 | 209 | PregLem SAINDUSTRY | 4 | Jan 15, 2016 | clinicaltrials |
| NCT01252069 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study) | completed | Phase 3 | 132 | PregLem SAINDUSTRY | 4 | Jan 13, 2016 | clinicaltrials |
| NCT01642472 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLext2) | completed | Phase 3 | 64 | PregLem SAINDUSTRY | 4 | Jan 8, 2016 | clinicaltrials |
| NCT00002706 | Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus | completed | Phase 3 | 2,616 | Gynecologic Oncology GroupNETWORK | 1 | May 29, 2015 | clinicaltrials |
| NCT00886873 | Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids(Mifemyo_2) | completed | Phase 2 / Phase 3 | 100 | Mediterranea Medica S. L.OTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT00712595 | Mifepristone for Treatment of Uterine Fibroids(Mifemyo) | completed | Phase 2 / Phase 3 | 200 | Mediterranea Medica S. L.OTHER | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00152256 | A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids | completed | Phase 3 | 239 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00156208 | Safety of Treatment of Uterine Fibroids With Asoprisnil | completed | Phase 3 | 166 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00156156 | Study of Asoprisnil in the Treatment of Uterine Fibroids. | completed | Phase 3 | 149 | AbbottINDUSTRY | 0 | May 28, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Nov 25, 2025source: clinicaltrials